Clinical Trial to Evaluate the Use of an Adsorption Membrane (oXiris®) During Cardiopulmonary Bypass Surgery

NACompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

October 31, 2015

Study Completion Date

October 31, 2015

Conditions
Cardiac Surgical ProceduresCardiopulmonary Bypass
Interventions
DEVICE

OXIRIS®

"OXIRIS® membrane set is composed of a 1.5 m2 copolymer of acrylonitrile and sodium methylsulfonate (AN 69) with polyethylenimine treated surface and adhered heparin during set´s fabrication \[OXIRIS® (Baxter Gambro)\].~PrismafleX eXeed™ II (Hospal) with OXIRIS® set will then be connected to CPB circuit. Blood flow between 150-200 ml/min will be derivatised from the CPB circuit into the PrismafleX eXeed™ so that it all flows through OXIRIS® membrane. Flow, pressure and alarms will be controlled by PrismafleX eXeed™ independently from CPB circuit.~OXIRIS® membrane will be only employed for adsorption (neither convection nor diffusion will be performed) during all CPB time."

Trial Locations (1)

08907

Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat

All Listed Sponsors
collaborator

Gambro Renal Products, Inc.

INDUSTRY

lead

Hospital Universitari de Bellvitge

OTHER

NCT02398019 - Clinical Trial to Evaluate the Use of an Adsorption Membrane (oXiris®) During Cardiopulmonary Bypass Surgery | Biotech Hunter | Biotech Hunter